Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Cross-sectional and Longitudinal Analysis

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2020 Dec 28

PMID 33362390

Citations 22

Authors

Peter Hoffmann

Victoria Jung

Rouven Behnisch

Annika Gauss

Affiliations

Soon will be listed here.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is common in the German population, with an even higher prevalence in inflammatory bowel disease patients.

Aim: To investigate the risk factors for NAFLD in inflammatory bowel disease patients.

Methods: This monocentric retrospective study with a cross-sectional and a longitudinal part included 694 patients. Inclusion criteria were diagnosed inflammatory bowel disease, age ≥ 18 years, availability of at least one abdominal ultrasound. Patients with infectious or suspected alcoholic fatty liver disease were excluded. NAFLD was defined by increased echogenicity at liver ultrasound. Demographic characteristics, disease activity and medications were analyzed as potential risk factors. Parameters influencing the course of NAFLD were identified by a generalized linear mixed model.

Results: Forty-eight percent of Crohn's disease (CD) patients and 44% of ulcerative colitis patients suffered from NAFLD. Its occurrence was associated with greater age, hypertension and body mass index (BMI) in both groups, and with higher disease activity and dyslipidemia in CD. 2467 ultrasound results were included in the longitudinal analysis. Risk factors for NAFLD were age, BMI, higher disease activity, bowel resection(s), endoscopic activity and azathioprine use in CD; and BMI and endoscopic activity in ulcerative colitis.

Conclusion: NAFLD was highly prevalent in this cohort of German inflammatory bowel disease patients. Its risk increased mainly with rising age and BMI. This analysis provides a rationale for non-invasive liver screening in inflammatory bowel disease patients.

Citing Articles

The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial.

Papaefthymiou A, Sarrou S, Pateras K, Vachliotis I, Agrotis G, Sgantzou I Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598344 PMC: 11597268. DOI: 10.3390/ph17111432.

Liver Fibrosis Index-4 Does Not Correlate to Liver Elastography in Patients with Inflammatory Bowel Disease.

Ferraz-Amaro I, Hernandez-Camba A, Carrillo-Palau M, Hernandez Alvarez-Buylla N, de Vera-Gonzalez A, Gonzalez-Delgado A J Clin Med. 2024; 13(21).

PMID: 39518569 PMC: 11546365. DOI: 10.3390/jcm13216430.

Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inﬂammatory bowel disease in tertiary center.

Oliveira L, Ribeiro T, Mourao Junior C, Barra M, Silva M, Shafee L Rev Assoc Med Bras (1992). 2024; 70(6):e20231321.

PMID: 39045949 PMC: 11288268. DOI: 10.1590/1806-9282.20231321.

Non-alcoholic fatty liver disease (NAFLD) and obesity in inflammatory bowel disease (IBD) patients in Gorgan.

Besharat S, Sakhavi F, Sookhtehsaraei P, Teimoorian M, Livani S, Norouzi A Caspian J Intern Med. 2024; 15(2):299-306.

PMID: 38807729 PMC: 11129069. DOI: 10.22088/cjim.15.2.299.

Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together.

Maresca R, Mignini I, Varca S, Calvez V, Termite F, Esposto G Int J Mol Sci. 2024; 25(6).

PMID: 38542249 PMC: 10970310. DOI: 10.3390/ijms25063278.

References

Fousekis F, Katsanos K, Theopistos V, Baltayiannis G, Kosmidou M, Glantzounis G . Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study. BMC Gastroenterol. 2019; 19(1):48. PMC: 6446300. DOI: 10.1186/s12876-019-0967-3. View

Bargiggia S, Maconi G, Elli M, Molteni P, Ardizzone S, Parente F . Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003; 36(5):417-20. DOI: 10.1097/00004836-200305000-00012. View

Walmsley R, Ayres R, Pounder R, Allan R . A simple clinical colitis activity index. Gut. 1998; 43(1):29-32. PMC: 1727189. DOI: 10.1136/gut.43.1.29. View

Harvey R, Bradshaw J . A simple index of Crohn's-disease activity. Lancet. 1980; 1(8167):514. DOI: 10.1016/s0140-6736(80)92767-1. View

Wang Y, Song J, Bian H, Bo J, Lv S, Pan W . Apelin promotes hepatic fibrosis through ERK signaling in LX-2 cells. Mol Cell Biochem. 2019; 460(1-2):205-215. PMC: 6745032. DOI: 10.1007/s11010-019-03581-0. View

Ge Y, Li Y, Chen Q, Zhu W, Zuo L, Guo Z . Adipokine apelin ameliorates chronic colitis in Il-10 mice by promoting intestinal lymphatic functions. Biochem Pharmacol. 2018; 148:202-212. DOI: 10.1016/j.bcp.2018.01.011. View

Adams L, Lymp J, Sauver J, Sanderson S, Lindor K, Feldstein A . The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129(1):113-21. DOI: 10.1053/j.gastro.2005.04.014. View

Saadeh S, Younossi Z, Remer E, Gramlich T, Ong J, Hurley M . The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(3):745-50. DOI: 10.1053/gast.2002.35354. View

Weidinger C, Ziegler J, Letizia M, Schmidt F, Siegmund B . Adipokines and Their Role in Intestinal Inflammation. Front Immunol. 2018; 9:1974. PMC: 6194904. DOI: 10.3389/fimmu.2018.01974. View

10.

Satsangi J, Silverberg M, Vermeire S, Colombel J . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55(6):749-53. PMC: 1856208. DOI: 10.1136/gut.2005.082909. View

11.

Zou Z, Shen B, Fan J . Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019; 25(11):1764-1772. DOI: 10.1093/ibd/izz043. View

12.

Xu Z, Li Y . Pathogenesis and treatment of parenteral nutrition-associated liver disease. Hepatobiliary Pancreat Dis Int. 2012; 11(6):586-93. DOI: 10.1016/s1499-3872(12)60229-x. View

13.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

14.

Dourakis S, Sevastianos V, Kaliopi P . Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol. 2002; 97(4):1074-5. DOI: 10.1111/j.1572-0241.2002.05644.x. View

15.

Barron L, Gayer C, Roberts A, Golden J, Aladegbami B, Guo J . Liver steatosis induced by small bowel resection is prevented by oral vancomycin. Surgery. 2016; 160(6):1485-1495. PMC: 5409838. DOI: 10.1016/j.surg.2016.07.018. View

16.

Adams L, Lubbe F, Bressem K, Wagner M, Hamm B, Makowski M . Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study. PLoS One. 2018; 13(11):e0206450. PMC: 6241122. DOI: 10.1371/journal.pone.0206450. View

17.

Han S, Wang G, Qiu S, de la Motte C, Wang H, Gomez G . Increased colonic apelin production in rodents with experimental colitis and in humans with IBD. Regul Pept. 2007; 142(3):131-7. DOI: 10.1016/j.regpep.2007.02.002. View

18.

Carr R, Patel A, Bownik H, Oranu A, Kerner C, Praestgaard A . Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients. Dig Dis Sci. 2017; 62(5):1354-1361. DOI: 10.1007/s10620-017-4495-0. View

19.

Maaser C, Sturm A, Vavricka S, Kucharzik T, Fiorino G, Annese V . ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2018; 13(2):144-164. DOI: 10.1093/ecco-jcc/jjy113. View

20.

Gaidos J, Fuchs M . Increased Prevalence of NAFLD in IBD Patients. Dig Dis Sci. 2017; 62(5):1362. DOI: 10.1007/s10620-017-4552-8. View